Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name LINC00673
   Synonyms LINC00673, HI-LNC75, HILNC75, LUCAIR1, SLNCR, SLNCR1, ERRLR01
   Region GRCh38_17:72403322-72592804    Sequence
   Ensembl NA
   RefSeq NR_036488
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name pancreatic cancer
   ICD-0-3 C25  
   Methods qPCR, Flow cytometry assay etc.
   Sample pancreatic cancer tissues, cell lines (BXPC-3 and CFPAC-1)
   Expression Pattern up-regulated
   Function Description

Flow cytometry analysis indicated that LINC00673 overexpression resulted in a substantial accumulation of PDAC cells in G0/G1 phase, accompanied by a substantial decrease in the number of cells in S phase. LINC00673 is able to reinforce the interaction of PTPN11 with PRPF19, an E3 ubiquitin ligase, and promote PTPN11 degradation through ubiquitination, which causes diminished SRC-ERK oncogenic signaling and enhanced activation of the STAT1-dependent antitumor response. A G>A change at rs11655237 in exon 4 of LINC00673 creates a target site for miR-1231 binding, which diminishes the effect of LINC00673 in an allele-specific manner and thus confers susceptibility to tumorigenesis.

   Pubmed ID 27213290
   Year 2016
   Title Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation.
   External Links
   Links for  LINC00673 GenBank       HGNC       lncrnadb       Noncode
   Links for  pancreatic cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.